Related Experiment Video
Updated: Apr 4, 2026

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
Published on: June 18, 2013
Enhanced anti-tumor efficacy and safety profile of tumor microenvironment-responsive oncolytic adenovirus nanocomplex
Joung-Woo Choi1, Kasala Dayananda1, Soo-Jung Jung1
1Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 133-791, Republic of Korea.
Abstract:
Oncolytic adenovirus (Ad) holds great promise as a potential gene therapy for cancer. However, intravenously administered Ad may encounter difficulties due to unfavorable host responses, non-specific interactions, and the heterogeneity of the tumor cell population. As an approach to combine the advantages of oncolytic Ad and synthetic polymers and to address the associated difficulties, Ad was physically complexed with a pH-sensitive block copolymer, methoxy poly(ethylene glycol)-b-poly(l-histidine) (mPEG-b-pHis). The in vitro transduction efficiency at an acidic extracellular pH was remarkably enhanced in cancer cells when treated with the Ad expressing green fluorescent protein (GFP) coated with mPEG-b-pHis (c-dE1/GFP) as compared to that of naked Ad (n-dE1/GFP). Time-lapse total internal reflection fluorescence microscopic imaging revealed a significantly enhanced cellular uptake rate of c-dE1/GFP at acidic tumor pH when compared with that at neutral pH or naked cognate Ad (n-dE1/GFP). In addition, c-dE1/GFP remained relatively stable in human serum-containing media, and considerably reduced both the innate and adaptive immune response against Ad. Moreover, the therapeutic efficacy and survival benefit of mPEG-b-pHis-complexed oncolytic Ad (c-H5mT/Luc) by systemic treatment was significantly enhanced compared to that with naked oncolytic Ad (n-H5mT/Luc) in both coxsackie and adenovirus receptor-positive and -negative tumors. Whole-body bioluminescence imaging showed 7.3-fold higher luciferase expression at the tumor site and 23.0-fold less luciferase expression in liver tissue for c-H5mT/Luc relative to that for naked oncolytic Ad (n-H5mT/Luc). Considering the heterogeneity of tumor tissue, these results are important for guiding the development of more potent and specific treatment of devastating metastatic cancers using this viral system.
Statement Of Significance:
Although adenoviral systems have shown considerable promise and undergone extensive evaluation attempts to specifically target Ad vectors to cancer cells have met limited success. This shortcoming is due to the strong immune response stimulated by Ad and the hepatotoxicity of the viral particles. To overcome restricted vector issues, we generated Ad/mPEG-b-pHis for tumor microenvironment-targeting hybrid vector systems, an oncolytic Ad coated with a pH-responsive polymer, mPEG-b-pHis. The Ad/mPEG-b-pHis exhibited pH-dependent transduction efficiency and cancer-cell killing effects. Moreover, systemic administration of oncolytic Ad/mPEG-b-pHis led to marked suppression of tumor growth and tumor-specific viral replication. Ad successfully avoided the innate and adaptive immune responses and liver accumulation with the help of mPEG-b-pHis on its surface.
Insights
Coating oncolytic adenoviruses (Ad) with a pH-sensitive polymer, mPEG-b-pHis, enhances cancer gene therapy. This hybrid vector targets tumors, improves transduction, and reduces immune response for better therapeutic efficacy.
Area of Science:
- Oncolytic virotherapy
- Polymer-drug conjugates
- Cancer gene therapy
Background:
- Oncolytic adenoviruses (Ad) show promise for cancer gene therapy but face challenges like immune responses and non-specific targeting.
- Systemic administration of Ad is hindered by host immune reactions and tumor heterogeneity.
Purpose of the Study:
- To develop a hybrid vector system combining oncolytic Ad with a pH-sensitive polymer, methoxy poly(ethylene glycol)-b-poly(l-histidine) (mPEG-b-pHis), to improve cancer targeting and therapeutic efficacy.
- To evaluate the in vitro and in vivo performance of Ad complexed with mPEG-b-pHis for enhanced tumor targeting and reduced immune response.
Main Methods:
- Adenovirus (Ad) was complexed with the pH-sensitive block copolymer mPEG-b-pHis to create a hybrid vector.
- In vitro studies assessed transduction efficiency at acidic vs. neutral pH and cellular uptake rates using GFP-expressing Ad.
- In vivo studies evaluated therapeutic efficacy, tumor-specific viral replication, immune response, and biodistribution using luciferase-expressing oncolytic Ad in tumor models.
Main Results:
- The mPEG-b-pHis-coated Ad (c-dE1/GFP) demonstrated significantly enhanced in vitro transduction efficiency in cancer cells at acidic pH compared to naked Ad.
- Time-lapse imaging showed increased cellular uptake of c-dE1/GFP at acidic tumor pH.
- Systemic administration of the mPEG-b-pHis-coated oncolytic Ad (c-H5mT/Luc) resulted in enhanced therapeutic efficacy, tumor growth suppression, and reduced liver accumulation compared to naked Ad.
- The hybrid vector significantly reduced innate and adaptive immune responses against the Ad.
Conclusions:
- The Ad/mPEG-b-pHis hybrid vector system exhibits pH-dependent targeting and enhanced cancer cell-killing effects.
- Systemic administration of oncolytic Ad/mPEG-b-pHis leads to marked tumor growth suppression and tumor-specific viral replication.
- The mPEG-b-pHis coating effectively shields Ad from immune responses and reduces liver accumulation, improving its potential for cancer gene therapy.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies

